These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 31641521)
1. Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen. Seufert J; Borck A; Bramlage P BMJ Open Diabetes Res Care; 2019; 7(1):e000679. PubMed ID: 31641521 [TBL] [Abstract][Full Text] [Related]
2. Methods to enhance delivery of prandial insulin and basal-prandial insulin. Garber AJ Diabetes Obes Metab; 2013 Mar; 15 Suppl 1():11-7. PubMed ID: 23448198 [TBL] [Abstract][Full Text] [Related]
3. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Raccah D; Huet D; Dib A; Joseph F; Landers B; Escalada J; Schmitt H Diabet Med; 2017 Sep; 34(9):1193-1204. PubMed ID: 28574177 [TBL] [Abstract][Full Text] [Related]
4. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Ilag LL; Kerr L; Malone JK; Tan MH Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926 [TBL] [Abstract][Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
6. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists? Darmon P; Raccah D Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016 [TBL] [Abstract][Full Text] [Related]
7. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403 [TBL] [Abstract][Full Text] [Related]
8. Basal plus basal-bolus approach in type 2 diabetes. Ampudia-Blasco FJ; Rossetti P; Ascaso JF Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S75-83. PubMed ID: 21668340 [TBL] [Abstract][Full Text] [Related]
9. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. Shaefer CF; Anderson J Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422 [TBL] [Abstract][Full Text] [Related]
10. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. Charbonnel B; Bertolini M; Tinahones FJ; Domingo MP; Davies M J Diabetes Complications; 2014; 28(6):880-6. PubMed ID: 25130920 [TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 diabetes. Vellanki P; Bean R; Oyedokun FA; Pasquel FJ; Smiley D; Farrokhi F; Newton C; Peng L; Umpierrez GE Diabetes Care; 2015 Apr; 38(4):568-74. PubMed ID: 25665812 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. Ericsson Å; Pollock RF; Hunt B; Valentine WJ J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661 [TBL] [Abstract][Full Text] [Related]
13. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775 [TBL] [Abstract][Full Text] [Related]
14. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. Pollock RF; Tikkanen CK J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031 [TBL] [Abstract][Full Text] [Related]
15. Premix insulins in type 1 diabetes: the coming of degludec/aspart. Rendell M Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):341-348. PubMed ID: 30789066 [TBL] [Abstract][Full Text] [Related]
16. Insulin therapy in type 2 diabetes: what is the evidence? van Avendonk MJ; Rutten GE Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375 [TBL] [Abstract][Full Text] [Related]
17. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G; Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747 [TBL] [Abstract][Full Text] [Related]
18. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349 [TBL] [Abstract][Full Text] [Related]
19. Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies. Umpierrez GE; Bailey TS; Carcia D; Shaefer C; Shubrook JH; Skolnik N J Diabetes; 2018 Feb; 10(2):94-111. PubMed ID: 28581207 [TBL] [Abstract][Full Text] [Related]
20. Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: results of the OSIRIS study. Raccah D; Haak TJ; Huet D; Monnier L; Robertson D; Labard P; Soler J; Penfornis A Diabetes Metab; 2012 Dec; 38(6):507-14. PubMed ID: 23116646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]